Advertisement

Picture Consultech GmbH Secure Funding with RnD Grants v7 650x100px
Organisation › Details

Centogene N.V. (Nasdaq: CNTG)

CENTOGENE’s mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases. We integrate multiomic technologies with the CENTOGENE Biodatabank – providing dimensional analysis to guide the next generation of precision medicine. Our unique approach enables rapid and reliable diagnosis for patients, supports a more precise physician understanding of disease states, and accelerates and de-risks targeted pharma drug discovery, development, and commercialization. Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis – building a network of approximately 30,000 active physicians. Our ISO, CAP, and CLIA certified multiomic reference laboratories in Germany utilize Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets. This data is captured in our CENTOGENE Biodatabank, with over 800,000 patients represented from over 120 highly diverse countries, over 70% of whom are of non-European descent. To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 285 peer-reviewed publications. By translating our data and expertise into tangible insights, we have supported over 50 collaborations with pharma partners. Together, we accelerate and de-risk drug discovery, development, and commercialization in target and drug screening, clinical development, market access and expansion, as well as offering CENTOGENE Biodata Licenses and Insight Reports to enable a world healed of all rare and neurodegenerative diseases. To discover more about our products, pipeline, and patient-driven purpose, visit www.centogene.com and follow us on LinkedIn. *

 

Period Start 2019-10-28 existent
  Group Centogene (Group)
Product Industry genomics
Persons Person Stratton, Kim (Centogene 202202– CEO before Orphazyme + Shire Pharmaceuticals + Novartis)
  Person 2 Coego Rios, Miguel (Centogene 202206– CFO joined as EVP Finance + Legal in 2/22 before Orphazyme + Mundipharma + Shire)
     
Region Region Netherlands_oo
  Country Netherlands
  City n. a. 
    Address record changed: 2020-12-02
     
Basic data Employees E: 501 to 1,000 (2021-12-31)
  Currency EUR
  Annual sales 189,923,000 (revenue (2021) 2021-12-31)
  Profit -46,852,000 (2021-12-31)
  Cash 17,818,000 (2021-12-31)
     
    * Document for »About Section«: Centogene N.V.. (2/28/24). "Press Release: Centogene Explores Strategic Alternatives". Cambridge, MA, Rostock & Berlin.
     
   
Record changed: 2024-03-13

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

More documents for Centogene (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x300px




» top